AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06264739
Drug: esp remifentanyl (ultiva)
RxNorm normalized name: remifentanil Injection [Ultiva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
Trial: NCT06369974
Drug: Antisense oligonucleotide treatment (ASO)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
Trial: NCT05497089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
Trial: NCT04946890
Drug: MRX2843
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
Trial: NCT00992238
Drug: Urispas® Tablets, 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05906836
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT05493462
Drug: Human FGF-1
RxNorm normalized name: herpesvirus 1, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration of human FGF-1
Trial: NCT04893980
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
Trial: NCT05057663
Drug: Bleomycin and 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions
Trial: NCT05214287
Drug: Hypoxic Gas Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
Trial: NCT04708340
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
Trial: NCT06727422
Drug: rifaximin 66mg + N-acetylcysteine 560mg three times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
Trial: NCT06727422
Drug: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
Trial: NCT06727422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo three times daily
Trial: NCT05863195
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05863195
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05506943
Drug: CTX-009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion on day 1 and 14 of every 28 day cycle
Trial: NCT05284656
Drug: combination of Pentoxifylline 400 MG and Folic Acid
RxNorm normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drugs used to delay progression of chronic kidney disease
Trial: NCT05284656
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drugs used to delay progression of chronic kidney disease
Trial: NCT00000635
Drug: Bacitracin zinc/Polymyxin B sulfate
RxNorm normalized name: bacitracin zinc/polymyxin B sulfate/pramoxine TOPICAL OINTMENT (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05135013
Drug: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration
Trial: NCT06471088
Drug: Dovprela
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose: 200 mg
Trial: NCT05754853
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT06673602
Drug: FCYC+Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
Trial: NCT06673602
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
Trial: NCT00254319
Drug: Avastin, Alimta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05573191
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT05003570
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Trial: NCT05003570
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Trial: NCT06235567
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
Trial: NCT06235567
Drug: topical prednisolone acetate 1% (PredForte) eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
Trial: NCT04890379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 240mg orally twice daily for 3 consecutive days
Trial: NCT05707871
Drug: SPECTRUM cigarettes
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECTRUM cigarettes have varying amount of nicotine content
Trial: NCT05371288
Drug: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
Trial: NCT04935073
Drug: Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
Trial: NCT05266417
Drug: Matched Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Matched Placebos Twice Daily
Trial: NCT05045261
Drug: Discontinuation of NUC treatment in arms B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC treatment will be stopped after 28 weeks in arms B and C
Trial: NCT06006650
Drug: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Trial: NCT05184517
Drug: Oph1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
Trial: NCT05001945
Drug: MLS-101 (Part I)
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLS-101 tablet(s) by mouth once or twice daily.
Trial: NCT05001945
Drug: MLS-101 (Part II)
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLS-101 tablet(s) by mouth once daily.
Trial: NCT05067387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT05067387
Drug: THC + CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC (20 mg) + CBD (20 mg)
Trial: NCT05325853
Drug: Proparacaine Ophthalmic
RxNorm normalized name: proparacaine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Proparacaine Hydrochloride
Trial: NCT04964557
Drug: AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Trial: NCT04964557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT05062577
Drug: ASP8062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05062577
Drug: Placebo ASP8062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT06577597
Drug: GSK3923868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of GSK3923868.
Trial: NCT06577597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of Placebo.
Trial: NCT04974957
Drug: SHR-1701；BP102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion
Trial: NCT05441267
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral semaglutide
Trial: NCT05032937
Drug: domestic polysaccharide superparamagnetic iron oxide nanoparticle
RxNorm normalized name: iron oxide, nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Trial: NCT05173896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of oral over-encapsulated placebo tablets for three months.
Trial: NCT06726564
Drug: MT027 cells suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Trial: NCT06725992
Drug: IY-NS250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 20mg + Sodium bicarbonate 500mg
Trial: NCT06726980
Drug: dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 5 % dextrose infusion
Trial: NCT06726980
Drug: Dextrose 10%
RxNorm normalized name: DEXTROSE 10% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 10 % dextrose infusion (25gm/ 250 mL)
Trial: NCT06726980
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive infused IV 0.9 % saline
Trial: NCT06726291
Drug: NEPA (300mg netupitant/0.5mg palonosetron)
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
Trial: NCT06727214
Drug: Chemotherapy with platine
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical records that patients received neoadjuvant systemic chemotherapy platine based
Trial: NCT05030168
Drug: Ketosteril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoanalogues of essential amino acid
Trial: NCT05488925
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Voltral SR100, 100 mg
Trial: NCT05488925
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feldene, 20 mg
Trial: NCT00117130
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00687180
Drug: Treatment with mycophenolat mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00687180
Drug: Treatment with azathioprin
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05065359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 0 mg, BID for 14 days
Trial: NCT04839016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05217160
Drug: KeraStat® Gel application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes.
Trial: NCT06068439
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
Trial: NCT06068439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
Trial: NCT05732493
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 d1-14 q3w
Trial: NCT06268054
Drug: DEH113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT06268054
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT05551858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avicel fiber filled capsule taken by mouth three times daily
Trial: NCT06167265
Drug: PMR Tablet 145 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (total daily dose of 290 mg)
Trial: NCT05046132
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules via oral administration.
Trial: NCT05046132
Drug: SC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via SC injection.
Trial: NCT04949633
Drug: Prostaglandins
RxNorm normalized name: PROSTAGLANDINS
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second cervical ripening lasting a maximum of 24 hours
Trial: NCT00004878
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05739903
Drug: DA-1229_01 5/1000mg (After)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05007522
Drug: Ketotifen/Indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tablet, 75 mg SR tablet
Trial: NCT05007522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT05126004
Drug: N Acetyl L Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
Trial: NCT04332666
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of NaCl 0.9% without diluted peptide in it
Trial: NCT05295940
Drug: LY3841136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05295940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT06300489
Drug: irinotecan liposomes+capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD).
Trial: NCT06458543
Drug: Longidaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
Trial: NCT04663750
Drug: subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
Trial: NCT05432713
Drug: LP-168 tablet
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Trial: NCT05432713
Drug: LP-168 Placebo tablet
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
Trial: NCT04871425
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl
Trial: NCT04003805
Drug: Standardized Research E-cigarette (SREC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
Trial: NCT00093210
Drug: rFIX
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00093210
Drug: rFIX-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no